Please login to the form below

Not currently logged in
Email:
Password:

EGFR

This page shows the latest EGFR news and features for those working in and with pharma, biotech and healthcare.

AZ forecasts growth in 2021 after revenues surge in Q4

AZ forecasts growth in 2021 after revenues surge in Q4

In 2020, oncology growth was up by 23% to $11.45bn, with the top-selling product being AZ’s EGFR-tyrosine kinase inhibitor Tagrisso (osimertinib).

Latest news

More from news
Approximately 7 fully matching, plus 169 partially matching documents found.

Latest Intelligence

  • Unlocking the potential of precision medicine in oncology Unlocking the potential of precision medicine in oncology

    Targeted therapies. Furthermore, by following a similar trajectory in the treatment of non-small cell lung cancer (NSCLC), where we are studying specific alterations in the epidermal growth factor receptor (EGFR), ... Our teams of clinical researchers

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Tagrisso’s growth as it moves earlier in the treatment pathway for EGFR-positive non-small lung cancer (NSCLC) and launches in new markets like China, plus possible label extensions for

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    Similarly, in other cancers, EGFR mutations, NTRK fusions and ALK fusions are all used as biomarkers because they indicate patients are likely to respond well to targeted therapies. ... The questions being asked are, what does an individual’s

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    lung cancer NSCLC patients with low PD-L1 expression (1%, also without EGFR or ALK mutations) – a group that was once thought unlikely to benefit from these drugs.

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    There is a good reason why Tagrisso was chosen for the fast track – the drug is for patients with epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung ... The EGFR mutation is particularly prevalent in Asian populations

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
Don’t limit diversity to just representation in clinical trials
What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...

Infographics